We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · August 11, 2022

Poziotinib for EGFR Exon 20–Mutant NSCLC

Cancer Cell

 

Additional Info

Cancer Cell
Poziotinib for EGFR exon 20-mutant NSCLC: Clinical efficacy, resistance mechanisms, and impact of insertion location on drug sensitivity
Cancer Cell 2022 Jul 11;40(7)754-767.e6, YY Elamin, JP Robichaux, BW Carter, M Altan, H Tran, DL Gibbons, S Heeke, FV Fossella, VK Lam, X Le, MV Negrao, MB Nilsson, A Patel, RSK Vijayan, JB Cross, J Zhang, LA Byers, C Lu, T Cascone, L Feng, R Luthra, FA San Lucas, G Mantha, M Routbort, G Blumenschein, AS Tsao, JV Heymach

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading